12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
Several healthcare stocks experienced significant movement in Tuesday's pre-market session. Vivos Therapeutics, Infinity Pharmaceuticals, Monopar Therapeutics, RxSight, Hims & Hers Health, and SILO Pharma saw increases, with Vivos Therapeutics leading with a 102.7% rise. Renovaro Biosciences, Vistagen Therapeutics, Maravai LifeSciences, ICU Medical, Inogen, and Enveric Biosciences experienced decreases, with Renovaro Biosciences leading the decline at 20.2%. Q2 earnings reports were released for RxSight, Hims & Hers Health, Maravai LifeSciences, ICU Medical, and Inogen.
August 08, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enveric Biosciences shares declined by 10.47% to $2.48.
The decline in Enveric Biosciences' share price is expected to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
ICU Medical stock declined by 11.93% to $151.0 after the Q2 earnings report.
The drop in ICU Medical's stock price following the Q2 earnings report is expected to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Inogen stock decreased by 11.34% to $6.65 after the Q2 earnings report.
The decrease in Inogen's stock price following the Q2 earnings report is likely to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Maravai LifeSciences shares declined by 12.89% to $9.6 after the Q2 earnings report.
The decline in Maravai LifeSciences' share price following the Q2 earnings report is likely to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Renovaro Biosciences stock decreased by 20.2% to $0.6 during Tuesday's pre-market session.
The significant decrease in Renovaro Biosciences' stock price is likely to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Vistagen Therapeutics shares fell 16.33% to $10.92.
The substantial drop in Vistagen Therapeutics' share price is expected to have a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Hims & Hers Health shares moved upwards by 15.06% to $9.09 after the Q2 earnings report.
The increase in Hims & Hers Health's share price following the Q2 earnings report is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Infinity Pharmaceuticals stock increased by 63.02% to $0.15.
The substantial rise in Infinity Pharmaceuticals' stock price is expected to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Monopar Therapeutics shares moved upwards by 16.54% to $0.88.
The increase in Monopar Therapeutics' share price is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
RxSight shares moved upwards by 16.15% to $33.5 after the Q2 earnings report.
The rise in RxSight's share price following the Q2 earnings report is expected to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
SILO Pharma stock rose 14.73% to $2.57.
The rise in SILO Pharma's stock price is expected to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Vivos Therapeutics shares moved upwards by 102.7% to $0.53 during Tuesday's pre-market session.
The significant increase in Vivos Therapeutics' share price is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100